Wilson named FOS executive director
Wilson previously served as the nonprofit's development director for six years.
'I am honored and humbled to take on this new role with Friends of Sinners,' Wilson said. 'The work we do here is more than just a program — it's a ministry, and it's my heart's desire to continue offering a path to recovery, hope and a restored life through the power of Christ. I've witnessed firsthand the incredible transformation that happens when individuals come to know Jesus and experience His healing. The staff we have here at Friends of Sinners is absolutely incredible and I look forward to leading this amazing team as we continue to serve those in need. I couldn't do this without my team behind me.'
Wilson is no stranger to the world of substance abuse because he's been personally engaged in a sobriety journey for nine years, and he has also volunteered with other organizations in the community in addition to FOS that focus on addiction, recovery and finding strength through Christ.
'Jordan has been actively involved in various recovery communities, mentoring others and sharing his testimony as a way of offering hope to those who feel lost in the darkness of addiction,' said the FOS Board of Directors in a Monday press release.
Board of directors members added, 'Jordan is a living testament to the power of faith, recovery and redemption. His journey has uniquely equipped him to lead Friends of Sinners into its next chapter, continuing the mission of providing hope, support and lasting change for individuals battling addiction. The board is confident in Jordan's experience in development and his heart for the mission of Friends of Sinners to work with and lead this exceptional group.'
During his time spent as the organization's development director, Wilson has helped to expand FOS's outreach and fundraising efforts.
In addition to keeping the FOS program running smoothly, looking forward, Wilson said that he would like to further expand the impact of FOS by fostering community relationships and 'ensuring that every person who comes to the ministry receives the love and support that they need to rebuild their lives.'
He's also excited to finally move into the program's new facility.
'We're hoping to get into the new facility at some point in 2025,' Wilson said. 'All of that depends on our Capital Campaign and support from the community.'
Wilson said that the organization has also recently launched its annual Gideons 300 giving campaign, which will run until mid-April. He hopes to exceed last year's giving campaign total of $75,000.
'Community support has just been amazing for Friends of Sinners since we're completely funded by donations. We rely on fundraisers in order to obtain our operating expenses,' he said.
Wilson also expressed a 'thank you' to his staff for 'working hard alongside him to see the organization's vision through.'
'I couldn't do this without all of my staff members. We make a great team,' he said. 'It's really a dream come true to be leading Friends of Sinners and I am so excited for the future.'
Wilson also encouraged individuals in the community who are interested in volunteering or donating to the organization to reach out to him at 270-689-9174.
'I can answer any questions that people might have about Friends of Sinners and I could even provide tours of the new facility if needed,' he said.
FOS has been providing faith-focused addiction recovery services to the Owensboro community for more than 15 years. The organization is committed to offering guidance to community members facing a recovery journey through faith, education and community by offering programs that focus on healing the mind, body and spirit.
More information about FOS, along with ways to donate or get involved with the nonprofit organization, can be found online at www.friendsofsinner.org.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
18-07-2025
- Business Insider
Telomir says data show Telomir-1 reversed epigenetic silencing
In a regulatory filing, Telomir Pharmaceuticals (TELO) reported new preclinical results evaluating the effects of its lead candidate, Telomir-1, in a murine xenograft model using PC3 human prostate cancer cells. The data demonstrated that Telomir-1 reversed epigenetic silencing by DNA methylation of the STAT1 gene, a tumor suppressor and immune response regulator, in a dose-dependent manner. STAT1 is frequently silenced in advanced cancers via promoter hypermethylation, disrupting immune detection and apoptotic pathways. In this study, Telomir-1 administered orally daily for 21 days resulted in full reversal of STAT1 hypermethylation in tumor tissue. No such reversal was observed in the Paclitaxel group, and only partial demethylation was observed with Rapamycin In addition to STAT1, Telomir-1 also reduced hypermethylation of TMS1, a pro-apoptotic tumor suppressor commonly silenced in prostate cancer. While PTX and Rapamycin showed comparable or greater effects on TMS1 methylation, Telomir-1 is unique in its ability to modulate both STAT1 and TMS1-two genes that together regulate immune response and apoptosis. Importantly, TMS1 also plays a central role in inflammasome activation, which not only contributes to tumor cell death but also supports the immune system's ability to detect and clear abnormal cells. When TMS1 is hypermethylated, this immune signaling pathway is disrupted-reducing caspase-1 activation and inflammatory cytokine release. This can impair immune surveillance and allow cancer cells to persist undetected. By reducing TMS1 hypermethylation, Telomir-1 may help restore immune recognition and enhance the tumor's sensitivity to both chemotherapy and immunotherapy. Telomere length analysis in PC3 tumor tissue showed no measurable elongation following Telomir-1 administration. This finding is relevant given concerns that telomere-targeting compounds may promote tumor progression through telomere extension in malignant cells. In contrast, Telomir-1 demonstrated selective activity without altering telomere length in this model. Telomir is conducting ongoing research to evaluate Telomir-1 across multiple therapeutic areas, including oncology, Wilson's disease, age-related macular degeneration, autism spectrum disorder, and dysphonia. The company is continuing preclinical development across these programs and plans to announce its initial IND indication at a future date. 'We remain encouraged by the preclinical data and continue to explore Telomir-1's potential across several disease areas. Our team is committed to advancing this program thoughtfully and strategically as we move toward clinical development,' said Erez Aminov, CEO of Telomir. Elevate Your Investing Strategy:
USA Today
15-07-2025
- USA Today
Medical debt remains on credit reports after Biden-era rule tossed by judge
Consumers were dealt a blow after a federal judge in Texas tossed out a Biden-era rule that would have banned the inclusion of medical debt on credit reports. In a move that advocates told USA TODAY eliminates a vital consumer protection, U.S. District Judge Sean Jordan on July 11 granted a request from President Donald Trump's administration and two financial industry groups to vacate the medical debt rule. The medical debt rule, finalized in January before former President Joe Biden left office, would've banned medical debt on credit reports and prohibited lenders from using a person's medical debt history to make lending decisions. The rule was scheduled to take effect in March, but the two trade groups sued the Consumer Financial Protection Bureau to halt the rule, and Jordan issued a stay, delaying the rule's start date. In late April, the Trump-appointed CFPB leadership opted not to oppose the lawsuit and filed a joint motion with the financial industry groups – the Consumer Data Industry Association and Cornerstone Credit Union League – to ask the judge to vacate the medical debt rule. Jordan, appointed during Trump's first administration, agreed with the trade groups that it was "fair, adequate and reasonable" to vacate the medical debt rule because it exceeded the CFPB's authority under the Fair Credit Reporting Act. Medical debt 'will likely get worse' Patricia Kelmar, senior director of health care campaigns at the U.S. PIRG Education Fund, said rule was necessary due to protect consumers from medical debt errors on credit reports. Medical bills accounted for more than half of debt collection on consumers' credit records, according to a 2022 report from the CFPB. "The problem is still here and will likely get worse," Kelmar said. "Medical debt on credit reports is disputed nearly three times as frequently as credit card debt." She said many of the 15 million Americans with medical debt on their credit reports are "penalized with lower credit scores, not because they owe the bill, but because they are still fighting it, or the hospitals reported it wrong." But industry groups cheered the decision. The medical debt rule would've potentially dealt lenders an "inaccurate and incomplete picture when making lending decisions," Dan Smith, president and CEO of the Consumer Data Industry Association, said in a statement. "Information about unpaid medical debts is an important element in assessing a consumer's ability to pay," Smith said. "This is the right outcome for protecting the integrity of the system." Paid medical debts, unpaid medical debts less than a year old and medical debts less than $500 already have been removed from credit reports by the three largest credit reporting companies. However, with the medical debt rule scrubbed, consumers can still expect larger medical debts to appear on credit reports. The decision comes as the Trump's sweeping tax cut and spending law could jeopardize health insurance coverage for millions of Americans in the coming years. The law would cut about $1 trillion from Medicaid and Affordable Care Act insurance plans, eliminating insurance coverage for 11.8 million people over the next decade, according to the nonpartisan Congressional Budget Office. Another 5 million could lose health insurance because the law doesn't extend Biden's COVID-19 pandemic-era tax credits that made ACA plans cheaper for consumers, according to a previous CBO analysis.
Medscape
14-07-2025
- Medscape
Are Americans Toking Themselves Sick?
This transcript has been edited for clarity. Welcome to Impact Factor , your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson from the Yale School of Medicine. Whenever you see a headline that says something is 'on the rise,' there are basically two possibilities. One, the thing is actually on the rise — like pickleball. The other possibility is that we're capturing the information differently nowadays. Either we are getting better at measuring something that has always been common (autism spectrum disorder may fall in this category, at least for part of the observed increase) or we are measuring something worse with more false positives driving up the observed rate, like UFO sightings. Ubiquitous phone cameras mean every little bit of swamp gas from a weather balloon trapped in a thermal pocket and reflecting the light from Venus gets recorded. It's the job of epidemiologists to figure out what is driving observed changes in our health, and this week I want to share some data that show that the rate of a specific cannabis-associated problem is not just on the rise; it is absolutely skyrocketing. Let's see if we can figure out why. I'm talking about cannabis hyperemesis syndrome (CHS), a once-rare condition characterized by cyclic episodes of what can be intractable vomiting. The exact physiology of CHS is still being worked out, but it probably has something to do with chronic exposure downregulating cannabinoid receptors in the gut, leading to decreased gut motility. Regardless of how exactly this works, the numbers suggest it is becoming dramatically more common — at least among adolescents, as highlighted in this research letter appearing in JAMA Network Open. Researchers interrogated the Pediatric Health Information System database which collates data from 52 free-standing children's hospitals around the United States. They were looking for adolescents admitted to the emergency department (ED) with diagnostic codes consistent with CHS, typically a chief complaint of nausea and vomiting, and at least a second diagnostic code indicating a 'cannabis-related concern.' These could be things like cannabis abuse or dependence. The time frame of interest was 2016 to 2023. Let's just take a look at the raw numbers. To give you some perspective, in 2006, there were 6.8 ED visits for CHS per 1 million population. In 2016, the start of this study, that number had jumped to 160.4, a more than 23-fold increase over a decade. These rates increased around 40% per year through 2023. The most recent data showed around 2000 visits for CHS per million population; that's a 30,000% increase in less than 20 years. Crazy numbers. But… are they real? Remember, when we see the rate of anything going up, we need to make sure we're not measuring it differently. And I certainly have some concern here that we are potentially unmasking a problem that has been there all along but not well documented until recently. Adolescents show up in the ED all the time for nausea and vomiting. The AHRQ publishes some of these data. For example, in 2018 there were nearly 800,000 visits for nausea and vomiting among those under age 18 — about 2.5% of all ED visits. The question is, how many of those had CHS? The study we're discussing this week would call it CHS if, in addition to the nausea and vomiting, they had a secondary code for a cannabis-related issue. I have no doubt that we use those codes more frequently now. For one thing, the broad-scale decriminalization and legalization of marijuana has removed much of the stigma that existed in the early 2000s. Doctors might be less worried about 'outing' these kids nowadays. Another possibility is that knowledge about CHS is spreading; with more marijuana use, doctors are getting more sensitive to the diagnosis. So perhaps some of those things we used to call a 'stomach bug' now get appropriately diagnosed as CHS. The converse could also be true. Since we're more comfortable adding cannabis-associated diagnosis codes now than we used to be in the past, we may currently be misclassifying people with nausea from another cause as CHS. Just because someone has cannabis use disorder or cannabis dependence doesn't mean they are not allowed to get norovirus. Of course, the other possibility is that there is a lot more marijuana use going on and with that, more CHS. The authors hypothesized that, if that were the case, we might see a more dramatic rise in states that have legalized recreational marijuana use. This is where the data get a bit weird. Because, yes, states with recreational marijuana legalization had more ED visits for CHS — overall, about 1900 cases per million vs 800 cases per million. But the rate of growth of those visits was more dramatic in states without recreational marijuana legalization. The authors don't opine on what would cause this pattern of observations. That's probably wise since the data are relatively limited. But that has never stopped me before, so here is what I think is going on. I think a lot of this is real. I suspect there is a true increase in the amount of CHS that is commensurate with the broader availability of marijuana in the marketplace. This leads to higher rates in states that have legalized recreational marijuana use. But a significant proportion of the observed increase is due to uncovering CHS in people who would not have received the diagnosis in the past and misclassification of non-CHS syndromes in the setting of people who happen to use marijuana. This occurs in states without legalized marijuana because, let's face it: Even in those states, the stigma about marijuana use is nowhere near what it was 10 or 20 years ago. The times they are a-changin', as one former pothead noted. Is this all a problem? CHS can be bad. In fact, just under half of the kids in this study required a hospital admission; a bit under 1% required the intensive care unit. That said, we should still contextualize these ED visits in the context of other risks adolescents face. I pulled a bit of data comparing ED visits for CHS to those for depression, suicide, gun violence, and drug overdoses. You can see here that CHS rates aren't as high as, say, ED visits for suicidal behavior, but these are all in the same ballpark. Of course, that's assuming the numbers in this study are not inflated. Still, it seems like we can add CHS to the list of real risks adolescents face in the United States today. And, if growth rates of the syndrome continue as they did in this study, rising by 50% per year, well, we can assume that every American adolescent will be in the ER for CHS by 2040. That would be… unlikely. But I suppose we can keep a bloodshot eye on it.
